Form4insider filings, from the source

SEC Form 4 · accession 0001140361-18-012008

CytomX Therapeutics, Inc. · CTMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Sean A. McCarthy
Officer — President and CEO · Director
Period of report
Mar 1, 2018
Accepted (ET)
Mar 5, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockMar 1, 2018M10,516$1.5749A15,159D
Common StockMar 1, 2018M9,000$1.1339A24,159D
Common StockMar 1, 2018M62$0.945A24,221D
Common StockF2Mar 1, 2018S19,578$29.428D4,643D
Common StockF3holding———154,237ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F4$1.5749Mar 1, 2018M10,516D—Feb 8, 2025Common Stock10,516194,804D
Stock Option (Right to Buy)F5$1.1339Mar 1, 2018M9,000D—Sep 20, 2021Common Stock9,000328,143D
Stock Option (Right to Buy)F5$0.945Mar 1, 2018M62D—Feb 25, 2023Common Stock6266,752D

Explanation of responses